Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Medical
- Supply
- Drugs
- Biotechnology
- Stem cells
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 294016
License Grant
The University grants an exclusive, license, including the right to grant sublicenses, under the Patent Rights, to make, have made, sell, offer for sale, have sold, use, import, and have imported Licensed Products in the Field.
License Property
The patents are for Non-Human Mammal Having a Graft and Methods of Delivering Protein to Myocardial Tissue; and. Myocardial Grafts and Cellular Composition.
Field of Use
Licensee develops and manufacture fully functioning human cells in industrial quantities to precise specifications. Licensee's proprietary iCell Operating System (iCell O/S) includes true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). iCell O/S products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use iCell O/S products, among other purposes, for drug discovery and screening; to test the safety and efficacy of their small molecule and biologic drug candidates; for stem cell banking; and in researching cellular therapeutics.
IPSCIO Record ID: 28403
License Grant
Licensor hereby grants to Licensee, and Licensee hereby accepts, subject to the terms and conditions hereof, a royalty bearing, exclusive license in the Territory in the Field and under the Licensed Technology to (a) research, develop, make, have made, use, sell, offer for sale, import and export Licensed Products, (b) research, develop, use, practice, sell, offer for sale, import and export Licensed Processes and (c) develop, use, perform, sell, offer for sale, import and export Licensed Services. By way of example, but not in limitation, Licensee shall have the right to use Licensed Technology within the Field to produce mammalian embryonic stem (ES) cells and to produce from those mammalian embryonic cells, differentiated cells for human therapeutic purposes or for commercial research purposes, including drug screening assays, and to produce pluripotent cells including ES cells, differentiated human cells for human diagnostic and therapeutic purposes and/or for commercial research purposes, including drug screening assays.
License Property
60/382,616 Nuclear Transfer-Generated Stem Cells for Transplantation Having Homozygous MHC Alleles, and Methods for Making and Using Such a Stem Cell Bank
09/736,268 Transfer to De-Differentiate Recipient Cells
Field of Use
Field shall mean (1) the research, development, manufacture and selling of human and non-human animal cells for commercial research use, including small molecule and other drug testing and basic research and (2) the manufacture and selling of human cells for therapeutic and diagnostic use in the treatment of human (a) diabetes and (b) liver diseases; but Field shall exclude applications involving the use of cells in the treatment of tumors where the primary use of the cells is the destruction or reduction of tumors and does not involve regeneration of tissue or organ function.
IPSCIO Record ID: 6732
License Grant
Foundation, formed by Licensee's President, grants an exclusive, worldwide, with the right to grant sublicenses through multiple tiers of sublicenses, in and to, the Technology, Licensed Products, Licensed Improvements, and Patents; and to develop, distribute, market, make, have made, use, have used, sell, have sold, offer for sale, and import Licensed Products.
License Property
The Licensor is engaged in research and development of stem cells and expansion laboratory services and interested in developing and commercializing the Technology.
The Licensee licensed from the Licensor the Stromal Cell technology for potential therapeutic use in the regrowth of damaged cardiac cells after a heart attack. The Licensor was formed by the Licensee President and its Chief Scientific Officer and Vice-President, to develop cellular technology for patients who have suffered myocardial infarctions.
The technology involves a method of preparing and using stromal cells for the treatment of cardiac diseases. A preferred embodiment of the technology is
a) enriching unique cells from bone marrow samples;
b) expanding these cells using a proprietary patent-pending method; and
c) harvesting the stromal cell product for potential therapeutic use
IPSCIO Record ID: 29009
License Grant
The University hereby grants Company the sole and exclusive, worldwide License to the Technology to develop, manufacture, use and sell Products.
License Property
Technology relate to developing Trade Secrets, Know-How and Patents dealing with methods, procedures and sciences relating to the science of enhancing fibroblast and other cellular ingrowth into homograft, xenograft and bioprosthetic grafts. Patent shall mean U.S. patent number 5,192,312.
An implantable human heart valve treated with growth factor effective on fibroblast cells and populated with fibroblast cells in an amount and for a time period effective for rendering the heart valve substantially non-immunogenic upon implant into a mammal. An implantable non-human mammalian heart valve treated with growth factor effective on fibroblast cells and populated with fibroblast cells in an amount and for a time period effective for rendering the heart valve substantially non-immunogenic upon implant into a mammal.
IPSCIO Record ID: 279305
License Grant
The Licensor of Japan grants a non-exclusive, non-transferable license, without the right to grant or authorize sublicenses except as expressly set forth, under the Licensed Patents to make, have made, use, develop, sell, offer to sell, and distribute, Licensed Pluripotent Cell Product in the Field and in the Territory.
Licensor grants a non-exclusive, non-transferable license, without the right to grant or authorize sublicenses except as expressly set forth, under the Licensed Patents to make, have made, use, develop, sell, offer to sell, and distribute the Licensed Differentiated Cell Products and Licensed Services in the Field and in the Territory.
License Property
Licensed Differentiated Cell Products means any products listed hereto, and any other products which may be added by mutual agreement in writing separately, which are made from induced pluripotent cells produced by methods covered by the Licensed Patents.
Licensed Pluripotent Cell Products means any induced pluripotent stem cell or induced pluripotent stem cell line produced by methods covered by the Licensed Patents.
Licensed Products means both Licensed Differentiated Cell Products and Licensed Pluripotent Cell Products including Cardiomyocytes, Hematopoeitic cells, Neural cells, Hepatocytes, Endothelial cells, Bone cells, Cartilage, Pancreatic cells, Fat cells and Lung cells.
The iPSC technology was pioneered Japan, who showed in 2006 that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells.
Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells.
Field of Use
The iPSC technology turned ordinary human skin cells into pluripotent stem cells, with the same characteristics and potential as embryonic stem cells.
Pluripotent stem cells hold promise in the field of regenerative medicine.[3] Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic, and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
